Professor Adrian Banning is a Consultant Cardiologist specialising in percutaneous coronary intervention.
He is the President of the British Cardiac Intervention Society and was previously the Divisional Director for Cardiology, Cardiothoracic and Vascular Surgery at the John Radcliffe University Hospital, Oxford. Through his position at the John Radcliffe, and his own practice at Oxford’s The Manor Hospital, Professor Banning provides specialist regional services for coronary and valvular heart disease patients to an area of 1.2 million people.
Professor Banning is pioneering research in his field and lectures nationally and internationally. He has authored several books on coronary intervention and has over 300 PUBMED listed scientific papers to his name.
23 Minutes – A video showing the speed at which Adrian and his team respond to save lives.
Research Highlights
Development of new procedures and research have been a passion for Professor Banning since the mid 1990s. He has investigated the mechanisms of vascular injury following revascularisation, studying the long-term prognostic implications, which have redefined our understanding of revascularisation injury.
Professor Banning was instrumental in the first clinical trials of drug eluting stents (DES) and he championed the use of intravascular ultrasound (IVUS) in the UK. This lead to his participation in landmark international interventional studies, such as TAXUS, Excel and Syntax. He is currently the co PI of the international Syntax 2 trial. which seeks to improve the assessment of risk in patients before choosing between drug eluting stents and coronary surgery.
Today, he is also pioneering Transcatheter Aortic Valve Implantation (TAVI) using the Lotus valve – an ultra-minimally invasive procedure.
